Overview

The Safety and Maximum Tolerated Dose of Axitinib in Combination With Radiotherapy for HCC

Status:
Completed
Trial end date:
2018-11-01
Target enrollment:
Participant gender:
Summary
To determine the maximal tolerated dose (MTD) of axitinib in combination with RT for advanced HCC.
Phase:
Phase 1
Details
Lead Sponsor:
Shin Kong Wu Ho-Su Memorial Hospital
Treatments:
Axitinib